Coherus BioSciences now has two biosimilars pending before the US Food and Drug Administration, after Formycon/Bioeq submitted to the agency their biosimilar Lucentis (ranibizumab) candidate for which Coherus holds US commercialization rights.
“Our next expected biosimilar launch is CHS-201, our Lucentis biosimilar candidate,” confirmed company chairman, president and CEO Denny Lanfear, speaking during
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?